Use of quality of life measures in mental health economics and care planning

Actas Espanolas de Psiquiatria

Volumn 34, Issue 1, 2006, Pages 1-6

  Ayuso Mateos, José Luis ^a,d   Salvador Carulla, L ^b   Chisholm, D ^c  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF CÁDIZ   (Spain)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Burden of disease; Cost utility; DALY; Mental health; Methods; QALY; Quality of life

Indexed keywords

ARTICLE; COST; ECONOMICS; HEALTH CARE PLANNING; HUMAN; MENTAL DISEASE; MENTAL HEALTH SERVICE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; SOCIOECONOMICS; UTILIZATION REVIEW;

COSTS AND COST ANALYSIS; HEALTH PLANNING; HUMANS; MENTAL DISORDERS; MENTAL HEALTH SERVICES; QUALITY OF LIFE; QUESTIONNAIRES; SOCIOECONOMIC FACTORS;

EID: 33645027800     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Chisholm D, Healey A, Knapp M. QALY and mental health care. Soc Psychiatry Psychiatr Epidemiol 1997;32:68-75.
2. Singh B, Hawthorne G, Vos T. The role of economic evaluation in mental health care. Aust N Z J Psychiatry 2001;35:104-17.
3. Healey A, Chisholm D. Willingness to pay as a measure of the benefits of mental health care. J Ment Health Policy Econ 1999;2:55-8.
4. Williams A. Economics of coronary-artery bypass-grafting. BMJ 1985;291:1507-8.
5. Murray CJL, López AD. Rethinking DALY. In: Murray CJL, López AD, editores. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press, 1996; p. 1-98.
6. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386-92.
7. Tan Torres T, Baltussen RM, Adam T. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003.
8. Chisholm D, Sanderson K, Ayuso-Mateos JL, Saxena S. Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions. Br J Psychiatry 2004;184:393-403.
9. Chisholm D, van Ommeren M, Ayuso-Mateos JL, Saxena S. Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder: a comparative analysis (WHO-CHOICE). Br J Psychiatry 2005;187:559-67.
10. Chisholm D, Rehm J, Van Ommeren M, Monteiro M. Reducing the global burden of hazardous alcohol use: a comparative cost-effectiveness analysis. J Stud Alcohol 2004;65:782-93.
11. Chisholm D. Cost-effectiveness of first-line antiepileptic drug treatments in the developing world: a population-level analysis. Epilepsia 2005;46:751-9.
12. Chisholm D. Choosing cost-effective interventions in psychiatry. World Psychiatry 2005 (en prensa).
13. Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Geneva: World Health Organization, 2001.
14. Valenstein M, Vijan S, Zeber JE, Boehm K, Buttar A. The cost-utility of screening for depression in primary care. Ann Intern Med 2001;134:345-60.
15. Kamlet MS, Wade M, Kupfer DJ, Frank E. Cost-utility analysis of maintenance treatment for recurrent depression: A theoretical framework and numerical illustration. En: Frank RG, Manning WG, editores. Economics and mental health. Baltimore: Johns Hopkins University Press, 1992; p. 267-91.
16. Hatziandreu EJ, Brown RE, Revicki DA, Turner R, Martindale J, Levine S, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics 1994;5:249-68.
17. Pyne JM, Smith J, Fortney J, Zhang M, Williams DK, Rost K. Cost-effectiveness of a primary care intervention for depressed females. J Affect Disord 2003;74:23-32.
18. Schoenbaum M, Unutzer J, Sherbourne C, Duan N, Rubenstein LV, Miranda J, et al. Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized controlled trial. JAMA 2001;286:1325-30.
19. Revicki DA, Brown RE, Keller MB, Gonzales J, Culpepper L, Hales RE. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry 1997;58:47-58.
20. Loomes G, McKenzie L. The scope and limitations of QALY measures. In: Baldwin S, Godfrey C, Propper C, editores. Quality of life perspectives and policies. London: Routledge, 1990; p. 84-102.
21. Cook KF, Ashton CM, Byrne MM, Brody B, Geraci J, Giesler RB, et al. A psychometric analysis of the measurement level of the rating scale, time trade-off, and standard gamble. Soc Sci Med 2001;53:1275-85.
22. Lenert L, Kaplan RM. Validity and interpretation of preference-based measures of health-related quality of life. Med Care 2000;38(9 Suppl. 11):138-50.
23. Prieto L, Sacristan JA. What is the value of social values? The uselessness of assessing health-related quality of life through preference measures. BMC Med Res Methodol 2004;4:10.
24. Cohen BJ. Is expected utility theory normative for medical decision making? Med Decis Mak 1996;16:1-6.